MARKET

VKTX

VKTX

Viking Therapeut
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.15
-0.20
-2.72%
Closed 19:56 09/13 EDT
OPEN
7.39
PREV CLOSE
7.35
HIGH
7.50
LOW
7.08
VOLUME
1.37M
TURNOVER
--
52 WEEK HIGH
24.00
52 WEEK LOW
6.53
MARKET CAP
516.31M
P/E (TTM)
-20.0617
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of VKTX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

VKTX News

  • Better Buy: Intercept Pharmaceuticals vs. Viking Therapeutics
  • Motley Fool.6d ago
  • Viking Therapeutics to Participate in Upcoming Investor Conferences
  • PR Newswire.08/28 12:30
  • The Daily Biotech Pulse: Roche Snags Double Nod For Personalized Cancer Drug, Bellicum Offering, Nabriva Braces For Contepo Resubmission
  • Benzinga.08/16 11:33
  • The Daily Biotech Pulse: Regeneron's Bad Cholesterol Drug Aces Late-Stage Trial, Oncolytics Offering
  • Benzinga.08/14 11:50

More

Industry

Biotechnology & Medical Research
+0.20%
Pharmaceuticals & Medical Research
-0.38%

Hot Stocks

Name
Price
%Change

About VKTX

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company's clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. VK5211 is a non-steroidal selective androgen receptor modulator (SARM). Its second program is focused on the development of orally available small molecule thyroid hormone receptor beta agonists. Its two molecules are VK2809 and VK0214. VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid beta receptor that is entering Phase II development for the treatment of patients with hypercholesterolemia and fatty liver disease. It is developing VK0214 for the treatment of X-linked adrenoleukodystrophy (X-ALD). It has a pipeline with approximately three additional programs targeting metabolic diseases and anemia.
More

Webull offers Viking Therapeutics Inc (VKTX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.